Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men

IF 10.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Marisel Rosell-Díaz , Anna Petit-Gay , Clàudia Molas-Prat , Laura Gallardo-Nuell , Lluís Ramió-Torrentà , Josep Garre-Olmo , Vicente Pérez-Brocal , Andrés Moya , Mariona Jové , Reinald Pamplona , Josep Puig , Rafael Ramos , Fredrik Bäckhed , Jordi Mayneris-Perxachs , José Manuel Fernández-Real
{"title":"Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men","authors":"Marisel Rosell-Díaz ,&nbsp;Anna Petit-Gay ,&nbsp;Clàudia Molas-Prat ,&nbsp;Laura Gallardo-Nuell ,&nbsp;Lluís Ramió-Torrentà ,&nbsp;Josep Garre-Olmo ,&nbsp;Vicente Pérez-Brocal ,&nbsp;Andrés Moya ,&nbsp;Mariona Jové ,&nbsp;Reinald Pamplona ,&nbsp;Josep Puig ,&nbsp;Rafael Ramos ,&nbsp;Fredrik Bäckhed ,&nbsp;Jordi Mayneris-Perxachs ,&nbsp;José Manuel Fernández-Real","doi":"10.1016/j.metabol.2024.155941","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly prescribed medication for the control of T2D and metformin treatment has been associated with a significant reduction in the risk of dementia and improved cognition, particularly in people with T2D.</p></div><div><h3>Aim</h3><p>To investigate the associations of metformin use with cognition exploring potential mechanisms by analyzing the gut microbiome and plasma metabolome using shotgun metagenomics and HPLC-ESI-MS/MS, respectively.</p></div><div><h3>Methods</h3><p>We explored two independent cohorts: an observational study (Aging Imageomics) and a phase IV, randomized, double-blind, parallel-group, randomized pilot study (MEIFLO). From the two studies, we analyzed four study groups: (1) individuals with no documented medical history or medical treatment (<em>n</em> = 172); (2) people with long-term T2D on metformin monotherapy (<em>n</em> = 134); (3) people with long-term T2D treated with oral hypoglycemic agents other than metformin (<em>n</em> = 45); (4) a newly diagnosed T2D subjects on metformin monotherapy (<em>n</em> = 22). Analyses were also performed stratifying by sex.</p></div><div><h3>Results</h3><p>Several bacterial species belonging to the Proteobacteria (<em>Escherichia coli</em>) and Verrucomicrobia (<em>Akkermansia muciniphila</em>) phyla were positively associated with metformin treatment, while bacterial species belonging to the Firmicutes phylum (<em>Romboutsia timonensis</em>, <em>Romboutsia ilealis</em>) were negatively associated. Due to the consistent increase in <em>A. muciniphila</em> and decrease in <em>R.ilealis</em> in people with T2D subjects treated with metformin, we investigated the association between this ratio and cognition. In the entire cohort of metformin-treated T2D subjects, the <em>A.muciniphila</em>/<em>R.ilealis</em> ratio was not significantly associated with cognitive test scores. However, after stratifying by sex, the <em>A.muciniphila</em>/<em>R. ilealis</em> ratio was significantly and positively associated with higher memory scores and improved memory in men.</p><p>Metformin treatment was associated with an enrichment of microbial pathways involved in the TCA cycle, and butanoate, arginine, and proline metabolism in both cohorts. The bacterial genes involved in arginine metabolism, especially in production of glutamate (<em>astA, astB, astC, astD, astE, putA</em>), were enriched following metformin intake. In agreement, in the metabolomics analysis, metformin treatment was strongly associated with the amino acid proline, a metabolite involved in the metabolism of glutamate.</p></div><div><h3>Conclusions</h3><p>The beneficial effects of metformin may be mediated by changes in the composition of the gut microbiota and microbial-host-derived co-metabolites.</p></div>","PeriodicalId":18694,"journal":{"name":"Metabolism: clinical and experimental","volume":"157 ","pages":"Article 155941"},"PeriodicalIF":10.8000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0026049524001689/pdfft?md5=0306d82cc1c5aa62af161906acde9ece&pid=1-s2.0-S0026049524001689-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolism: clinical and experimental","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0026049524001689","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background

An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly prescribed medication for the control of T2D and metformin treatment has been associated with a significant reduction in the risk of dementia and improved cognition, particularly in people with T2D.

Aim

To investigate the associations of metformin use with cognition exploring potential mechanisms by analyzing the gut microbiome and plasma metabolome using shotgun metagenomics and HPLC-ESI-MS/MS, respectively.

Methods

We explored two independent cohorts: an observational study (Aging Imageomics) and a phase IV, randomized, double-blind, parallel-group, randomized pilot study (MEIFLO). From the two studies, we analyzed four study groups: (1) individuals with no documented medical history or medical treatment (n = 172); (2) people with long-term T2D on metformin monotherapy (n = 134); (3) people with long-term T2D treated with oral hypoglycemic agents other than metformin (n = 45); (4) a newly diagnosed T2D subjects on metformin monotherapy (n = 22). Analyses were also performed stratifying by sex.

Results

Several bacterial species belonging to the Proteobacteria (Escherichia coli) and Verrucomicrobia (Akkermansia muciniphila) phyla were positively associated with metformin treatment, while bacterial species belonging to the Firmicutes phylum (Romboutsia timonensis, Romboutsia ilealis) were negatively associated. Due to the consistent increase in A. muciniphila and decrease in R.ilealis in people with T2D subjects treated with metformin, we investigated the association between this ratio and cognition. In the entire cohort of metformin-treated T2D subjects, the A.muciniphila/R.ilealis ratio was not significantly associated with cognitive test scores. However, after stratifying by sex, the A.muciniphila/R. ilealis ratio was significantly and positively associated with higher memory scores and improved memory in men.

Metformin treatment was associated with an enrichment of microbial pathways involved in the TCA cycle, and butanoate, arginine, and proline metabolism in both cohorts. The bacterial genes involved in arginine metabolism, especially in production of glutamate (astA, astB, astC, astD, astE, putA), were enriched following metformin intake. In agreement, in the metabolomics analysis, metformin treatment was strongly associated with the amino acid proline, a metabolite involved in the metabolism of glutamate.

Conclusions

The beneficial effects of metformin may be mediated by changes in the composition of the gut microbiota and microbial-host-derived co-metabolites.

二甲双胍诱导的肠道微生物组和血浆代谢组变化与男性认知能力有关。
背景:以产生丁酸的细菌数量减少和基因丰富度降低为特征的肠道微生物组改变与 2 型糖尿病(T2D)有关。2 型糖尿病的一个重要并发症是认知障碍和痴呆的风险增加。双胍类药物二甲双胍是控制 T2D 的常用处方药,二甲双胍治疗与显著降低痴呆症风险和改善认知能力有关,尤其是在 T2D 患者中。目的:分别使用枪弹元基因组学和 HPLC-ESI-MS/MS 分析肠道微生物组和血浆代谢组,研究二甲双胍的使用与认知能力的关系,探索潜在的机制:我们研究了两个独立的队列:一项观察性研究(Aging Imageomics)和一项第四阶段随机、双盲、平行组、随机试验研究(MEIFLO)。从这两项研究中,我们分析了四个研究组:(1)无病史记录或未接受过医疗的个人(n = 172);(2)长期接受二甲双胍单药治疗的 T2D 患者(n = 134);(3)长期接受二甲双胍以外的口服降糖药治疗的 T2D 患者(n = 45);(4)新诊断的 T2D 患者,接受二甲双胍单药治疗(n = 22)。此外,还按性别进行了分层分析:结果:属于变形菌门(大肠杆菌)和疣状芽胞杆菌门(Akkermansia muciniphila)的几种细菌与二甲双胍治疗呈正相关,而属于固着菌门(Romboutsia timonensis、Romboutsia ilealis)的细菌呈负相关。由于使用二甲双胍治疗的 T2D 患者中,粘液虹彩菌(A. muciniphila)持续增加,而回肠虹彩菌(R.ilealis)持续减少,因此我们研究了这一比例与认知能力之间的关系。在所有接受二甲双胍治疗的 T2D 受试者中,A.muciniphila/R.ilealis 比率与认知测试得分无显著关联。然而,按性别分层后,回肠黏液比值与男性的记忆力评分和记忆力改善呈显著正相关。二甲双胍治疗与两个队列中参与 TCA 循环、丁酸盐、精氨酸和脯氨酸代谢的微生物通路的富集有关。摄入二甲双胍后,参与精氨酸代谢,尤其是谷氨酸生产的细菌基因(astA、astB、astC、astD、astE、putA)丰富。同样,在代谢组学分析中,二甲双胍治疗与氨基酸脯氨酸密切相关,而脯氨酸是参与谷氨酸代谢的代谢物:结论:二甲双胍的有益作用可能是由肠道微生物群组成的变化和微生物-宿主衍生的共代谢物介导的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Metabolism: clinical and experimental
Metabolism: clinical and experimental 医学-内分泌学与代谢
CiteScore
18.90
自引率
3.10%
发文量
310
审稿时长
16 days
期刊介绍: Metabolism upholds research excellence by disseminating high-quality original research, reviews, editorials, and commentaries covering all facets of human metabolism. Consideration for publication in Metabolism extends to studies in humans, animal, and cellular models, with a particular emphasis on work demonstrating strong translational potential. The journal addresses a range of topics, including: - Energy Expenditure and Obesity - Metabolic Syndrome, Prediabetes, and Diabetes - Nutrition, Exercise, and the Environment - Genetics and Genomics, Proteomics, and Metabolomics - Carbohydrate, Lipid, and Protein Metabolism - Endocrinology and Hypertension - Mineral and Bone Metabolism - Cardiovascular Diseases and Malignancies - Inflammation in metabolism and immunometabolism
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信